Nadda chairs Joint Strategy Meeting with Line Ministries for TB Mukt Bharat Abhiyan- 100-Day Intensified Campaign
The company reported a net profit of Rs 46.15 crore in Q2 FY25 as compared to Rs 23.88 crore in Q2 FY24
These initiatives signify a substantial boost to healthcare infrastructure across India, aligned with the Prime Minister’s mission of ensuring quality healthcare services nationwide
There is an urgent need for more therapeutic treatment options for patients with painful osteoarthritis
The Profit After Tax (PAT) for Q4 FY24 at Rs 36.40 crore, compared to Rs 38.23 crore in Q4 FY23
EBITDA for Q3 FY24 almost tripled to reach Rs. 41.49 crore
Parecoxib Sodium is the first parenteral selective COX-2 inhibitor available for clinical use in pain management
Take proper precautions and seek timely treatment!
The new range of HDPE bottles is compliant with US FDA, EU regulations and Chinese DMF registration for use in dry pharmaceutical applications
Themis will market this drug with the brand name REMITHEM.
Subscribe To Our Newsletter & Stay Updated
